133 related articles for article (PubMed ID: 1804789)
21. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
[TBL] [Abstract][Full Text] [Related]
22. Treating acute exacerbations of chronic bronchitis in the face of antibiotic resistance.
Adams SG; Anzueto A
Cleve Clin J Med; 2000 Sep; 67(9):625-8, 631-3. PubMed ID: 10992620
[TBL] [Abstract][Full Text] [Related]
23. Cefuroxime axetil vs. augmentin for the treatment of acute bronchitis and exacerbation of chronic obstructive pulmonary disease.
Landau Z; Schlaffer F; Pitlik S
Isr J Med Sci; 1992 Nov; 28(11):797-9. PubMed ID: 1468894
[No Abstract] [Full Text] [Related]
24. Hyponatremia after initiation and rechallenge with trimethoprim-sulfamethoxazole in an older adult.
Huntsberry AM; Linnebur SA; Vejar M
Clin Interv Aging; 2015; 10():1091-6. PubMed ID: 26170649
[TBL] [Abstract][Full Text] [Related]
25. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study.
Creemers-Schild D; Kroon FP; Kuijper EJ; de Boer MG
Infection; 2016 Jun; 44(3):291-9. PubMed ID: 26471512
[TBL] [Abstract][Full Text] [Related]
27. Parenteral ofloxacin in treatment of pyelonephritis.
Cox CE
Urology; 1991; 37(3 Suppl):16-20. PubMed ID: 2003340
[TBL] [Abstract][Full Text] [Related]
28. Trimethoprim-sulfamethoxazole in chronic bronchitis.
Jordan GW; Krajden SF; Hoeprich PD; Wong GA; Peirce TH; Rausch DC
Can Med Assoc J; 1975 Jun; 112(13 Spec No):91-5. PubMed ID: 1137833
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim-sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection.
Gomolin IH; Siami PF; Reuning-Scherer J; Haverstock DC; Heyd A;
J Am Geriatr Soc; 2001 Dec; 49(12):1606-13. PubMed ID: 11843992
[TBL] [Abstract][Full Text] [Related]
31. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial.
Klein NC; Duncanson FP; Lenox TH; Forszpaniak C; Sherer CB; Quentzel H; Nunez M; Suarez M; Kawwaff O; Pitta-Alvarez A
AIDS; 1992 Mar; 6(3):301-5. PubMed ID: 1567574
[TBL] [Abstract][Full Text] [Related]
32. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.
Miller LG; Daum RS; Creech CB; Young D; Downing MD; Eells SJ; Pettibone S; Hoagland RJ; Chambers HF;
N Engl J Med; 2015 Mar; 372(12):1093-103. PubMed ID: 25785967
[TBL] [Abstract][Full Text] [Related]
33. A prospective study of ofloxacin in acute exacerbations of chronic respiratory disease associated with Pseudomonas aeruginosa.
Meek JC; Maesen FP; Davies BI
J Antimicrob Chemother; 1989 Sep; 24(3):447-53. PubMed ID: 2808196
[TBL] [Abstract][Full Text] [Related]
34. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study.
Shah PM; Maesen FP; Dolmann A; Vetter N; Fiss E; Wesch R
J Antimicrob Chemother; 1999 Apr; 43(4):529-39. PubMed ID: 10350383
[TBL] [Abstract][Full Text] [Related]
35. A multicenter study of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated acute pyelonephritis.
Mouton Y; Ajana F; Chidiac C; Capron MH; Home P; Masquelier AM
Am J Med; 1992 Apr; 92(4A):87S-90S. PubMed ID: 1316078
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the safety and efficacy of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated urinary tract infections: results from a multicenter study.
Andrade-Villanueva J; Flores-Gaxiola A; Lopez-Guillen P; Aguirre-Avalos G; Morfin-Otero R; Rodriguez-Noriega E
Am J Med; 1992 Apr; 92(4A):71S-74S. PubMed ID: 1316074
[TBL] [Abstract][Full Text] [Related]
37. [Update on the use of levofloxacin in the management of acute exacerbations of chronic bronchitis with risk factors].
Zuck P
Presse Med; 2002 Jun; 31(21 Pt 2):S15-8. PubMed ID: 12148385
[TBL] [Abstract][Full Text] [Related]
38. Interstitial lung disease during trimethoprim/sulfamethoxazole administration.
Yuzurio S; Horita N; Shiota Y; Kanehiro A; Tanimoto M
Acta Med Okayama; 2010 Jun; 64(3):181-7. PubMed ID: 20596129
[TBL] [Abstract][Full Text] [Related]
39. Treatment of exacerbations of chronic bronchitis. A comparative double-blind study with cotrimoxazole and cefadroxil.
Ruiz J; Garcia J; Martinez ML; Navarro A; Cuatrecasas JM; Morera J
Int J Clin Pharmacol Res; 1984; 4(5):355-9. PubMed ID: 6394515
[TBL] [Abstract][Full Text] [Related]
40. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
